Walleye Capital
DYN icon

Walleye Capital’s Dyne Therapeutics DYN Stock Holding History

Walleye Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,762
Closed -$543K – 4533
2025
Q4 		$543K Buy
+27,762
New +$526K ﹤0.01% 2911
2025
Q2 		– Sell
-154,634
Closed -$1.62M – 4615
2025
Q1 		$1.62M Buy
+154,634
New +$2.21M 0.01% 1586
2024
Q3 		– Sell
-85,652
Closed -$3.02M – 5414
2024
Q2 		$3.02M Buy
+85,652
New +$2.49M 0.01% 1718
2023
Q4 		– Sell
-280,276
Closed -$2.51M – 5074
2023
Q3 		$2.51M Buy
+280,276
New +$3.02M 0.01% 1553
2021
Q2 		– Sell
-20,000
Closed -$311 – 1384
2021
Q1 		$311 Buy
+20,000
New +$387K 0.02% 738

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Walleye Capital's DYN Position: Q1 2026 in Review

Walleye Capital sold out of Dyne Therapeutics (DYN) in Q1 2026, closing a stake of 27,762 shares — an estimated $543K sold.

Walleye Capital first reported a position in DYN in Q1 2021 and held it in 5 quarters. The position peaked at $3.02M in Q2 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Walleye Capital reported no remaining Dyne Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 27,762 Dyne Therapeutics shares in Q1 2026, an estimated $543K.
  • Walleye Capital first reported a position in Dyne Therapeutics in Q1 2021 and held it in 5 quarters.
  • Walleye Capital's Dyne Therapeutics position peaked at $3.02M in Q2 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.